top of page
The Professional Network for Healthcare Experts
FDA approves first-in-class targeted therapy daraxonrasib for metastatic pancreatic cancer
The approval introduces the first RAS(ON) inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma with a KRAS G12X mutation, establishing a new biomarker-directed option for one of the hardest-to-treat cancers.
nuaxia
Aug 272 min read
A Standing Ovation for a New Chapter in Pancreatic Cancer
Daraxonrasib, KRAS G12D, and the ASCO26 Signal That Broke a Long Silence
nuaxia
Jun 34 min read
FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer
Wearable TTFields device now authorised in combination with chemotherapy following Phase III PANOVA-3 trial demonstrating overall survival benefit.
nuaxia
Feb 161 min read
bottom of page